• 4250 Citations
  • 36 h-Index
1984 …2022

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

Dr. Prokai is the first Chair in Biochemistry endowed by the Houston-based Welch Foundation, one of the United States’ oldest and largest private funding sources for basic research, at UNT Health Science Center. He is affiliated with UNTHSC’s Department of Pharmacology and Neuroscience, and with the Institute of Healthy Aging. Dr. Prokai also is Adjunct Professor at the Department of Chemistry and Biochemistry, University of Texas at Arlington, as well as Adjunct Professor and Associate Member of the Graduate Faculty at the Department of Chemistry and Biochemistry of Texas Christian University.
His interests focus on chemistry-driven multidisciplinary research and include the discovery, chemical biology, bioorganic, and medicinal chemistry of central nervous system agents, as well as neuropeptides, proteomics, and mass spectrometry.
Dr. Prokai has maintained an actively funded research program from grant support by the National Institutes of Health (NIH) as well as through collaborations with pharmaceutical and chemical companies. Dr. Prokai was the recipient of the 2017 Wilfred T. Doherty Award of the Dallas/Fort Worth Section of the American Chemical Society (ACS) and the 2017 Southwest ACS Regional Award.

Education/Academic qualification

PhD in Radiochemistry, University of Veszprem

Award Date: 1 Jan 2003

BS in Chemical Engineering, University of Veszprem

Award Date: 1 Jan 2001

MS in Chemistry, University of Veszprem

Award Date: 1 Jan 2001

Fingerprint Dive into the research topics where Laszlo Prokai is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

[ 99 mTc-HYNIC-N-dodecylamide]:a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging

Isaac-Olivé, K., Ocampo-García, B. E., Aranda-Lara, L., Santos-Cuevas, C. L., Jiménez-Mancilla, N. P., Luna-Gutiérrez, M. A., Medina, L. A., Nagarajan, B., Sabnis, N., Raut, S., Prokai, L. & Lacko, A. G., 14 Jan 2019, In : Nanoscale. 11, 2, p. 541-551 11 p.

Research output: Contribution to journalArticle

  • 1 Scopus citations

    Brain delivery of thyrotropin-releasing hormone via a novel prodrug approach

    Prokai-Tatrai, K., De La Cruz, D. L., Nguyen, V., Ross, B. P., Toth, I. & Prokai, L., Jul 2019, In : Pharmaceutics. 11, 7, 349.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Different reactivity to glutathione but similar tumor cell toxicity of chalcones and their quinolinone analogues

    d’Oliveira, G. D. C., Custodio, J. M. F., Moura, A. F., Napolitano, H. B., Pérez, C. N., Moraes, M. O., Prókai, L. & Perjési, P., 1 Sep 2019, In : Medicinal Chemistry Research. 28, 9, p. 1448-1460 13 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    An exploratory investigation of brain-selective estrogen treatment in males using a mouse model of Alzheimer's disease

    Tschiffely, A. E., Schuh, R. A., Prokai-Tatrai, K., Ottinger, M. A. & Prokai, L., Feb 2018, In : Hormones and Behavior. 98, p. 16-21 6 p.

    Research output: Contribution to journalArticle

  • 8 Scopus citations